146 related articles for article (PubMed ID: 32000270)
1. Efficacy and Safety of Psychostimulants for Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Kishi T; Sakuma K; Iwata N
Pharmacopsychiatry; 2020 Apr; 53(3):109-114. PubMed ID: 32000270
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial.
Rosenberg PB; Lanctôt KL; Drye LT; Herrmann N; Scherer RW; Bachman DL; Mintzer JE; ADMET Investigators
J Clin Psychiatry; 2013 Aug; 74(8):810-6. PubMed ID: 24021498
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological interventions for apathy in Alzheimer's disease.
Ruthirakuhan MT; Herrmann N; Abraham EH; Chan S; Lanctôt KL
Cochrane Database Syst Rev; 2018 May; 5(5):CD012197. PubMed ID: 29727467
[TBL] [Abstract][Full Text] [Related]
4. Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial.
Padala PR; Padala KP; Lensing SY; Ramirez D; Monga V; Bopp MM; Roberson PK; Dennis RA; Petty F; Sullivan DH; Burke WJ
Am J Psychiatry; 2018 Feb; 175(2):159-168. PubMed ID: 28945120
[TBL] [Abstract][Full Text] [Related]
5. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge.
Herrmann N; Rothenburg LS; Black SE; Ryan M; Liu BA; Busto UE; Lanctôt KL
J Clin Psychopharmacol; 2008 Jun; 28(3):296-301. PubMed ID: 18480686
[TBL] [Abstract][Full Text] [Related]
6. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial.
Scherer RW; Drye L; Mintzer J; Lanctôt K; Rosenberg P; Herrmann N; Padala P; Brawman-Mintzer O; Burke W; Craft S; Lerner AJ; Levey A; Porsteinsson A; van Dyck CH;
Trials; 2018 Jan; 19(1):46. PubMed ID: 29347996
[TBL] [Abstract][Full Text] [Related]
7. Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial).
Zeng L; Perin J; Gross AL; Shade D; Lanctôt KL; Lerner AJ; Mintzer JE; Brawman-Mintzer O; Padala PR; van Dyck CH; Porsteinsson AP; Craft S; Levey A; Herrmann N; Rosenberg PB
Int J Geriatr Psychiatry; 2024 Jun; 39(6):e6108. PubMed ID: 38858522
[TBL] [Abstract][Full Text] [Related]
8. Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial.
Mintzer J; Lanctôt KL; Scherer RW; Rosenberg PB; Herrmann N; van Dyck CH; Padala PR; Brawman-Mintzer O; Porsteinsson AP; Lerner AJ; Craft S; Levey AI; Burke W; Perin J; Shade D;
JAMA Neurol; 2021 Nov; 78(11):1324-1332. PubMed ID: 34570180
[TBL] [Abstract][Full Text] [Related]
9. Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial.
Lanctôt KL; Chau SA; Herrmann N; Drye LT; Rosenberg PB; Scherer RW; Black SE; Vaidya V; Bachman DL; Mintzer JE
Int Psychogeriatr; 2014 Feb; 26(2):239-46. PubMed ID: 24169147
[TBL] [Abstract][Full Text] [Related]
10. Methylphenidate and Other Pharmacologic Treatments for Apathy in Alzheimer's Disease.
Andrade C
J Clin Psychiatry; 2022 Feb; 83(1):. PubMed ID: 35120284
[TBL] [Abstract][Full Text] [Related]
11. Improvement of neuronal integrity with methylphenidate treatment for apathy in Alzheimer's disease.
Padala PR; Padala KP; Samant RS; James GA
Int Psychogeriatr; 2020 Apr; 32(4):539-540. PubMed ID: 32019622
[No Abstract] [Full Text] [Related]
12. Methylphenidate for apathy and functional status in dementia of the Alzheimer type.
Padala PR; Burke WJ; Shostrom VK; Bhatia SC; Wengel SP; Potter JF; Petty F
Am J Geriatr Psychiatry; 2010 Apr; 18(4):371-4. PubMed ID: 20220576
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of methylphenidate for the treatment of apathy in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled studies.
Lee CW; Chen JY; Ko CC; Chuang MH; Tsai WW; Sun CK; Hung KC
Psychopharmacology (Berl); 2022 Dec; 239(12):3743-3753. PubMed ID: 36243827
[TBL] [Abstract][Full Text] [Related]
14. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Epstein T; Patsopoulos NA; Weiser M
Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
[TBL] [Abstract][Full Text] [Related]
15. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
16. Selegiline for Alzheimer's disease.
Birks J; Flicker L
Cochrane Database Syst Rev; 2003; (1):CD000442. PubMed ID: 12535396
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild-to-moderate Alzheimer's disease.
Frakey LL; Salloway S; Buelow M; Malloy P
J Clin Psychiatry; 2012 Jun; 73(6):796-801. PubMed ID: 22687392
[TBL] [Abstract][Full Text] [Related]
18. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue.
Minton O; Richardson A; Sharpe M; Hotopf M; Stone P
J Natl Cancer Inst; 2008 Aug; 100(16):1155-66. PubMed ID: 18695134
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease.
Breitbart W; Rosenfeld B; Kaim M; Funesti-Esch J
Arch Intern Med; 2001 Feb; 161(3):411-20. PubMed ID: 11176767
[TBL] [Abstract][Full Text] [Related]
20. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial.
Ravindran AV; Kennedy SH; O'Donovan MC; Fallu A; Camacho F; Binder CE
J Clin Psychiatry; 2008 Jan; 69(1):87-94. PubMed ID: 18312042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
